A shuttered Milanese manufacturing site with a storied history is getting a new lease on life, thanks to a nearly half-a-billion-dollar investment from Italian drugmaker Chiesi. As part of an ongoing ...

As health systems seek to balance innovation with the need to address sustainability, increasing attention is being paid to ...

Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, ...

Findings showed BDP/FF/G improved predose FEV1 and reduced the rate of moderate to severe exacerbations compared with BDP/FF. The Food and Drug Administration (FDA) has accepted for review the New ...

Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers 1, ensuring patients ...